Giving comprehensive consideration to the overall survival of NASH patients, the potential therapeutic effects obtained through the STAT-1 or STAT-3 signaling pathway can also serve to prevent advancement to liver failure as well as hepatocarcinogenesis. This evidence concerns the gene STAT3 and metabolic dysfunction-associated steatohepatitis.